Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C R Franks

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
European Journal of Cancer & Clinical Oncology|January 1, 1989
Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II studyE Shiloni, P Pouillart, J Janssens, et al.
British Journal of Cancer|May 1, 1992
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinomaS Négrier, A Mercatello, M Bret, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinomaP A Palmer, J Vinke, P Evers, et al.
Cancer Research|May 1, 1991
Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2F Velotti, A Stoppacciaro, L Ruco, et al.
Immunology Letters|July 1, 1992
Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical responseR Isacson, E Kedar, V Barak, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1989
Analysis of parameters for maximal in vitro proliferation and activation of lymphokine-activated killer cells (LAK)C Coze, V Combaret, I Philip, et al.
Cancer Treatment Reviews|June 1, 1989
A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignanciesA Lindemann, K Hoeffken, R E Schmidt, et al.
Cancer Treatment Reviews|June 1, 1989
Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre studyG Stoter, S D Fosså, C Rugarli, et al.
Molecular Biotherapy|March 1, 1990
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient studyJ Atzpodien, A Körfer, P Evers, et al.
Cancer|April 1, 1991
The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2H Kirchner, A Körfer, P Evers, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
European Journal of Cancer & Clinical Oncology|January 1, 1989
Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II studyE Shiloni, P Pouillart, J Janssens, et al.
British Journal of Cancer|May 1, 1992
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinomaS Négrier, A Mercatello, M Bret, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinomaP A Palmer, J Vinke, P Evers, et al.
Cancer Research|May 1, 1991
Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2F Velotti, A Stoppacciaro, L Ruco, et al.
Immunology Letters|July 1, 1992
Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical responseR Isacson, E Kedar, V Barak, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1989
Analysis of parameters for maximal in vitro proliferation and activation of lymphokine-activated killer cells (LAK)C Coze, V Combaret, I Philip, et al.
Cancer Treatment Reviews|June 1, 1989
A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignanciesA Lindemann, K Hoeffken, R E Schmidt, et al.
Cancer Treatment Reviews|June 1, 1989
Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre studyG Stoter, S D Fosså, C Rugarli, et al.
Molecular Biotherapy|March 1, 1990
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient studyJ Atzpodien, A Körfer, P Evers, et al.
Cancer|April 1, 1991
The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2H Kirchner, A Körfer, P Evers, et al.
Pageof 10